» Articles » PMID: 37874478

Racial and Socioeconomic Disparities in Survival Among Women with Advanced-stage Ovarian Cancer Who Received Systemic Therapy

Overview
Specialties Oncology
Public Health
Date 2023 Oct 24
PMID 37874478
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The purpose of this study was to assess the association between race/ethnicity and all-cause mortality among women with advanced-stage ovarian cancer who received systemic therapy.

Methods: We analyzed data from the National Cancer Database on women diagnosed with advanced-stage ovarian cancer from 2004 to 2015 who received systemic therapy. Race/ethnicity was categorized as Non-Hispanic (NH) White, NH-Black, Hispanic, NH-Asian/Pacific Islander, and Other. Income and education were combined to form a composite measure of socioeconomic status (SES) and categorized into low-, mid-, and high-SES. Multivariable Cox proportional hazards models were used to assess whether race/ethnicity was associated with the risk of death after adjusting for sociodemographic, clinical, and treatment factors. Additionally, subgroup analyses were conducted by SES, age, and surgery receipt.

Results: The study population comprised 53,367 women (52.4% ages ≥ 65 years, 82% NH-White, 8.7% NH-Black, 5.7% Hispanic, and 2.7% NH-Asian/Pacific Islander) in the analysis. After adjusting for covariates, the NH-Black race was associated with a higher risk of death versus NH-White race (aHR: 1.12; 95% CI: 1.07,1.18), while Hispanic ethnicity was associated with a lower risk of death compared to NH-White women (aHR: 0.87; 95% CI: 0.80, 0.95). Furthermore, NH-Black women versus NH-White women had an increased risk of mortality among those with low-SES characteristics (aHR:1.12; 95% CI:1.03-1.22) and mid-SES groups (aHR: 1.13; 95% CI:1.05-1.21).

Conclusions: Among women with advanced-stage ovarian cancer who received systemic therapy, NH-Black women experienced poorer survival compared to NH-White women. Future studies should be directed to identify drivers of ovarian cancer disparities, particularly racial differences in treatment response and surveillance.

Citing Articles

Patient Characteristics Associated with Time to Next Treatment in Patients with Ovarian Cancer Treated with Niraparib: The PRED1CT Real-World Study.

Chase D, Shukla S, Moore J, Boyle T, Lim J, Perhanidis J Oncol Ther. 2024; 12(3):599-607.

PMID: 39097531 PMC: 11333773. DOI: 10.1007/s40487-024-00294-3.


Global, regional, and national burden of ovarian cancer among young women during 1990-2019.

Zhuang Q, Gu G, Chen J, Tang Z, Wu C, Liu J Eur J Cancer Prev. 2024; 34(1):1-10.

PMID: 38837195 PMC: 11620324. DOI: 10.1097/CEJ.0000000000000899.

References
1.
Park H, Ruterbusch J, Cote M . Recent Trends in Ovarian Cancer Incidence and Relative Survival in the United States by Race/Ethnicity and Histologic Subtypes. Cancer Epidemiol Biomarkers Prev. 2017; 26(10):1511-1518. PMC: 6859937. DOI: 10.1158/1055-9965.EPI-17-0290. View

2.
Reid F, Bhatla N, Oza A, Blank S, Cohen R, Adams T . The World Ovarian Cancer Coalition Every Woman Study: identifying challenges and opportunities to improve survival and quality of life. Int J Gynecol Cancer. 2020; 31(2):238-244. DOI: 10.1136/ijgc-2019-000983. View

3.
Hildebrand J, Wallace K, Graybill W, Kelemen L . Racial disparities in treatment and survival from ovarian cancer. Cancer Epidemiol. 2018; 58:77-82. DOI: 10.1016/j.canep.2018.11.010. View

4.
Montes de Oca M, Wilson L, Previs R, Gupta A, Joshi A, Huang B . Healthcare Access Dimensions and Guideline-Concordant Ovarian Cancer Treatment: SEER-Medicare Analysis of the ORCHiD Study. J Natl Compr Canc Netw. 2022; 20(11):1255-1266.e11. DOI: 10.6004/jnccn.2022.7055. View

5.
Zamarin D, Burger R, Sill M, Powell Jr D, Lankes H, Feldman M . Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. J Clin Oncol. 2020; 38(16):1814-1823. PMC: 7255977. DOI: 10.1200/JCO.19.02059. View